A pair of med tech companies--Intersect ENT and Ocular Therapeutix--are on the road and ready for an IPO this week. Both of these companies have high-profile corporate investors, Medtronic and Baxter, respectively. They are trying to cash in on the recently renewed, public investor interest in life science IPOs to raise the money to market FDA-approved products and advance pipelines.
Two weeks after scoring an FDA nod for its innovative robotic exoskeleton, ReWalk Robotics is marching to market with a $58 million initial public offering.
CardioDx, the heart disease test developer that delayed plans to go public in November due to poor market conditions, has decided to test the IPO waters again. This time it will be doing it with some new leadership.
Stentmaker Lombard Medical has set the range for its pending U.S. IPO, aiming to raise $60 million with the sale of 3.6 million shares priced between $15 and $18.
Biomet, a maker of medical devices based in Warsaw, IN, has reportedly filed with U.S. regulators for an IPO nominally valued at $100 million.
Israel's Lumenis is bucking the hesitance of many medical device companies to pursue the public markets and is moving ahead with its IPO plans. The maker of minimally invasive medical lasers released further details in a recent regulatory filing, noting that it wants to sell 6.3 million shares and raise approximately $100 million.
Amedica has priced its public offering, and in doing so has lowered expectations for the second time this week. The Utah medical device company said it will roll out of the gate with an offering of 3.5 million shares of common stock at $5.75 per share, a price much lower than the company initially proposed.
Diagnostics wunderkind Foundation Medicine has made its way to the Nasdaq, hauling in a $106 million IPO at the top of its range.
Put lightly, it was less than a banner year for medical device and diagnostics companies looking to go public. Check out the report >>
Cancer Genetics will ramp up clinical trials plus expand its sales and marketing staff with an initial public offering the company envisions will haul in close to $49 million.